CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today that it has been added as a member of the Russell 2000® and Russell 3000® Indexes after the close of market yesterday, March 31, 2014.
Help employers find you! Check out all the jobs and post your resume.
